APGE
NASDAQApogee Therapeutics Inc.
News25/Ratings12
Price$134.85+52.53 (+63.81%)
2026-05-212026-08-25
News · 26 weeks82+14%
2026-03-012026-08-23
Mix4190d
- Insider16(39%)
- SEC Filings15(37%)
- Other8(20%)
- Earnings2(5%)
Latest news
25 items- INSIDERDirector Fairmount Funds Management Llc exercised 42,208 shares at a strike of $23.60 (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form 10-Q filed by Apogee Therapeutics Inc.10-Q - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- PRApogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline UpdatesAbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today reported second quarter 20
- INSIDERChief Medical Officer Dambkowski Carl sold $737,935 worth of shares (5,500 units at $134.17) as part of a pre-agreed trading plan and exercised 4,125 shares at a strike of $22.86, decreasing direct ownership by 0.81% to 168,498 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- INSIDERChief Financial Officer Henderson Jane gifted 15,000 shares, decreasing direct ownership by 9% to 158,371 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERChief Medical Officer Dambkowski Carl gifted 8,000 shares, decreasing direct ownership by 4% to 169,873 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECSEC Form DEFM14A filed by Apogee Therapeutics Inc.DEFM14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- INSIDERChief Executive Officer Henderson Michael Thomas sold $2,672,600 worth of shares (20,000 units at $133.63) as part of a pre-agreed trading plan and gifted 75,046 shares, decreasing direct ownership by 9% to 920,941 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- INSIDERChief Medical Officer Dambkowski Carl sold $730,070 worth of shares (5,500 units at $132.74) as part of a pre-agreed trading plan and exercised 4,125 shares at a strike of $22.86, decreasing direct ownership by 0.77% to 177,873 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECSEC Form PREM14A filed by Apogee Therapeutics Inc.PREM14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- INSIDERChief Medical Officer Dambkowski Carl sold $3,500,640 worth of shares (26,400 units at $132.60) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 179,248 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERChief Executive Officer Henderson Michael Thomas sold $10,603,200 worth of shares (80,000 units at $132.54) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 1,015,987 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Apogee Therapeutics Inc.SCHEDULE 13D/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form 144 filed by Apogee Therapeutics Inc.144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
APGE FAQ
6 questionsWhere does APGE stock trade?
Apogee Therapeutics Inc. (APGE) is listed on NASDAQ.What sector and industry is APGE in?
Apogee Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Apogee Therapeutics Inc. go public?
Apogee Therapeutics Inc. (APGE) completed its IPO in 2023.What are analysts saying about APGE?
Apogee Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Rothschild & Co Redburn: Buy on 2026-05-01.What companies are similar to APGE?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare APGE side-by-side with any of them on Quantisnow.How can I track APGE on Quantisnow?
Quantisnow aggregates Apogee Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APGE to receive live email and push alerts on every new disclosure.